Oxyntomodulin: The Dual GLP-1/Glucagon Agonist and Its Weight Loss Potential
Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS
Oxyntomodulin, a natural dual GLP-1/glucagon agonist, reduces appetite while increasing energy expenditure, offering a balanced approach to weight loss.
The success of incretin-based therapies in obesity and diabetes management has spurred interest in other gut hormones that modulate appetite and metabolism. Oxyntomodulin (OXM), a naturally occurring peptide, stands out due to its unique dual agonism of both glucagon-like peptide-1 (GLP-1) and glucagon receptors. This dual action positions OXM and its analogs as promising candidates for weight loss, offering a balanced approach to energy balance regulation.
What is Oxyntomodulin?
Oxyntomodulin is a 37-amino acid peptide hormone derived from the same proglucagon precursor as GLP-1 and glucagon. It is secreted from intestinal L-cells post-prandially, in proportion to caloric intake [1]. While it shares structural similarities with both GLP-1 and glucagon, its physiological effects are distinct, reflecting its ability to activate both receptor types.
Dual Mechanism of Action: Appetite Suppression and Energy Expenditure
OXM's therapeutic potential stems from its unique dual agonism, which simultaneously targets two critical pathways involved in energy homeostasis:
Appetite Suppression: Reduces food intake by acting on central nervous system pathways involved in satiety [2].
Delayed Gastric Emptying: Slows the rate at which food leaves the stomach, prolonging feelings of fullness.
Glucose-Dependent Insulin Secretion: Enhances insulin release in response to elevated blood glucose, contributing to glycemic control.
Increased Energy Expenditure: Stimulates thermogenesis, particularly in brown adipose tissue, leading to increased calorie burning [3].
Lipolysis: Promotes the breakdown of fat stores, contributing to fat mass reduction.
Hepatic Glucose Production (with caveats): While glucagon typically increases hepatic glucose production, the concurrent GLP-1 agonism and overall metabolic improvements with OXM often mitigate this effect, leading to a net beneficial impact on glucose homeostasis, especially in the context of weight loss.
This combination of reduced caloric intake (via GLP-1 agonism) and increased energy expenditure (via glucagon agonism) makes OXM a particularly attractive target for obesity pharmacotherapy.
Clinical Evidence and Therapeutic Development
Early clinical studies with exogenous OXM administration have demonstrated its efficacy in promoting weight loss and improving metabolic parameters:
Reduced Food Intake: Intravenous infusion of OXM in healthy and obese individuals has been shown to significantly reduce ad libitum food intake and decrease overall calorie consumption [4].
Weight Loss: Chronic administration of OXM or its analogs has led to significant reductions in body weight and fat mass in both preclinical models and human trials. For instance, a 4-week study showed that OXM administration resulted in a mean weight loss of 2.3 kg [5].
Improved Glucose Homeostasis: OXM has also been shown to improve insulin sensitivity and reduce fasting glucose levels, indicating benefits beyond just weight loss.
Despite its promising effects, native OXM has a very short half-life, necessitating continuous infusion or frequent injections, which limits its clinical utility. Therefore, significant research efforts are focused on developing long-acting OXM analogs or co-agonists that can be administered less frequently, similar to the advancements seen with GLP-1 receptor agonists.
The Future of OXM Analogs
The development of stable, long-acting OXM analogs or multi-agonists that include OXM's effects represents a significant frontier in obesity medicine. These next-generation therapies aim to harness the synergistic benefits of dual GLP-1 and glucagon agonism to provide even more potent and sustained weight loss, potentially surpassing the efficacy of current monotherapies. The balanced action on both sides of the energy balance equation—reducing intake and increasing expenditure—offers a comprehensive strategy for combating obesity and its associated metabolic complications.
Conclusion
Oxyntomodulin, with its unique dual agonism of GLP-1 and glucagon receptors, offers a compelling physiological blueprint for effective weight loss. By simultaneously suppressing appetite and boosting energy expenditure, OXM and its synthetic analogs hold immense potential as next-generation pharmacotherapies for obesity. As research continues to overcome pharmacokinetic challenges, OXM-based treatments are poised to become a vital tool in the fight against the global obesity epidemic, providing a more holistic approach to metabolic health.
References
[1] Wynne, K., et al. (2005). Oxyntomodulin increases energy expenditure in obese humans. Diabetes, 54(Suppl 1), A17. https://diabetesjournals.org/diabetes/article/54/suppl_1/A17/13379/Oxyntomodulin-increases-energy-expenditure-in
[2] Cohen, M. A., et al. (2003). Oxyntomodulin suppresses appetite and reduces food intake in humans. Journal of Clinical Endocrinology & Metabolism, 88(10), 4696–4701. https://pubmed.ncbi.nlm.nih.gov/14557462/
[3] Lockie, S. H., et al. (2012). Oxyntomodulin: a potential therapeutic for obesity. Endocrinology, 153(2), 621–629. https://pubmed.ncbi.nlm.nih.gov/22186154/
[4] Neary, N. M., et al. (2005). Oxyntomodulin reduces food intake in obese humans. Journal of Clinical Endocrinology & Metabolism, 90(3), 1752–1755. https://pubmed.ncbi.nlm.nih.gov/15598692/
[5] Small, C. J., et al. (2006). The effect of oxyntomodulin on appetite and weight in humans. International Journal of Obesity, 30*(Suppl 1), S10–S14. https://pubmed.ncbi.nlm.nih.gov/16570020/